As previously announced, Elanco Animal Health has entered into a development and commercialization agreement with VetDC, Inc. to become the exclusive distributor of TANOVEA-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved drug for the treatment of lymphoma in dogs. This collaboration between VetDC, Inc. and Elanco Animal Health includes on-going clinical trials in support of full TANOVEA-CA1 approval. Now that our collaboration is in effect, we want to update you on an important change to our ordering process.
Please contact Elanco Animal Health Customer Service at 1.800.782.8977 or email at email@example.com to place all TANOVEA-CA1 orders.
We are excited to partner with Elanco Animal Health to bring this important canine lymphoma treatment to veterinary clinics. Both Elanco Animal Health and VetDC, Inc. are strongly committed to the animal health industry and will continue to seek opportunities to deliver greater innovation and value to our customers.
Please do not hesitate to contact Elanco Animal Health Customer Service or VetDC, Inc. if you have any questions. We appreciate your patience during this transition and thank you for the opportunity to serve your business.